Xtl Biopharmaceuticals Stock Current Ratio
| XTLB Stock | ILS 5.80 0.60 11.54% |
XTL Biopharmaceuticals fundamentals help investors to digest information that contributes to XTL Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of XTL Stock. The fundamental analysis module provides a way to measure XTL Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XTL Biopharmaceutica stock.
XTL |
XTL Biopharmaceuticals Company Current Ratio Analysis
XTL Biopharmaceutica's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current XTL Biopharmaceutica Current Ratio | 51.07 X |
Most of XTL Biopharmaceutica's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XTL Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, XTL Biopharmaceuticals has a Current Ratio of 51 times. This is much higher than that of the sector and significantly higher than that of the Current Ratio industry. The current ratio for all Israel stocks is notably lower than that of the firm.
XTL Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XTL Biopharmaceutica's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XTL Biopharmaceutica could also be used in its relative valuation, which is a method of valuing XTL Biopharmaceutica by comparing valuation metrics of similar companies.XTL Biopharmaceutica is currently under evaluation in current ratio category among its peers.
XTL Fundamentals
| Return On Equity | 0.38 | |||
| Return On Asset | -0.1 | |||
| Current Valuation | 61.84 M | |||
| Shares Outstanding | 514.21 M | |||
| Shares Owned By Insiders | 16.20 % | |||
| Price To Earning | 558.33 X | |||
| EBITDA | (940 K) | |||
| Net Income | 435 K | |||
| Cash And Equivalents | 5.06 M | |||
| Cash Per Share | 0.01 X | |||
| Current Ratio | 51.07 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (1.05 M) | |||
| Beta | 1.03 | |||
| Market Capitalization | 236.53 K |
About XTL Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XTL Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XTL Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XTL Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in XTL Stock
XTL Biopharmaceutica financial ratios help investors to determine whether XTL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XTL with respect to the benefits of owning XTL Biopharmaceutica security.